BeiGene’s Brukinsa (zanubrutinib) Receives EC’s Approval for the Treatment Chronic Lymphocytic Leukemia
Shots:
- The EC has approved Brukinsa in adult patients with TN or r/r CLL
- The approval was based on the P-III (SEQUOIA) and (ALPINE) trial evaluating zanubrutinib (BTK inhibitor) vs bendamustine + rituximab or ibrutinib in 740 & 652 which showed superior efficacy in both trials & superiority to chemoimmunotherapy, ORR (80.4% vs 72.9%), and patients had a sustained response @1yr. with rates of 90% vs 78%, favorable safety profile incl. lower rates of AF/flutter
- The therapy has been approved in the EU for WM in adult patients who have received 1 prior therapy or as a 1L treatment for patients unsuitable for chemoimmunotherapy & for MZL who have received 1 prior anti-CD20-based therapy
Ref: Businesswire | Image: BeiGene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
